SELLAS Life Sciences Group, Inc.

Phase 2 AI-extracted

SLS009

Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML)

Countdown

86days

Phase 2 readout · ~ Sep 30, 2026 estimated

What's at stake Phase 2 trial results for SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 11h ago

“The topline data are expected in Q4 2026.”

Add to calendar Post on X Reddit

Provenance